Your browser doesn't support javascript.
loading
Integrated epigenomic exposure signature discovery.
Schuetter, Jared; Minard-Smith, Angela; Hill, Brandon; Beare, Jennifer L; Vornholt, Alexandria; Burke, Thomas W; Murugan, Vel; Smith, Anthony K; Chandrasekaran, Thiruppavai; Shamma, Hiba J; Kahaian, Sarah C; Fillinger, Keegan L; Amper, Mary Anne S; Cheng, Wan-Sze; Ge, Yongchao; George, Mary Catherine; Guevara, Kristy; Lovette-Okwara, Nora; Mahajan, Avinash; Marjanovic, Nada; Mendelev, Natalia; Fowler, Vance G; McClain, Micah T; Miller, Clare M; Mofsowitz, Sagie; Nair, Venugopalan D; Nudelman, German; Evans, Thomas G; Castellino, Flora; Ramos, Irene; Rirak, Stas; Ruf-Zamojski, Frederique; Seenarine, Nitish; Soares-Shanoski, Alessandra; Vangeti, Sindhu; Vasoya, Mital; Yu, Xuechen; Zaslavsky, Elena; Ndhlovu, Lishomwa C; Corley, Michael J; Bowler, Scott; Deeks, Steven G; Letizia, Andrew G; Sealfon, Stuart C; Woods, Christopher W; Spurbeck, Rachel R.
Afiliación
  • Schuetter J; Health Business Unit, Battelle Memorial Institute, Columbus, OH 43201, USA.
  • Minard-Smith A; Health Business Unit, Battelle Memorial Institute, Columbus, OH 43201, USA.
  • Hill B; Nationwide Insurance, Columbus, OH 43215, USA.
  • Beare JL; Health Business Unit, Battelle Memorial Institute, Columbus, OH 43201, USA.
  • Vornholt A; Icahn School of Medicine at Mount Sinai, New York City, NY 10029, 10029USA.
  • Burke TW; Division of Infectious Diseases, Duke University, Durham, NC 27710, USA.
  • Murugan V; Center for Personalized Diagnostics, Biodesign Institute at Arizona State University, Tempe, AZ 85281, 85281USA.
  • Smith AK; Health Business Unit, Battelle Memorial Institute, Columbus, OH 43201, USA.
  • Chandrasekaran T; Center for Personalized Diagnostics, Biodesign Institute at Arizona State University, Tempe, AZ 85281, 85281USA.
  • Shamma HJ; Health Business Unit, Battelle Memorial Institute, Columbus, OH 43201, USA.
  • Kahaian SC; Health Business Unit, Battelle Memorial Institute, Columbus, OH 43201, USA.
  • Fillinger KL; Health Business Unit, Battelle Memorial Institute, Columbus, OH 43201, USA.
  • Amper MAS; Icahn School of Medicine at Mount Sinai, New York City, NY 10029, 10029USA.
  • Cheng WS; Icahn School of Medicine at Mount Sinai, New York City, NY 10029, 10029USA.
  • Ge Y; Icahn School of Medicine at Mount Sinai, New York City, NY 10029, 10029USA.
  • George MC; Icahn School of Medicine at Mount Sinai, New York City, NY 10029, 10029USA.
  • Guevara K; Icahn School of Medicine at Mount Sinai, New York City, NY 10029, 10029USA.
  • Lovette-Okwara N; Icahn School of Medicine at Mount Sinai, New York City, NY 10029, 10029USA.
  • Mahajan A; Icahn School of Medicine at Mount Sinai, New York City, NY 10029, 10029USA.
  • Marjanovic N; Icahn School of Medicine at Mount Sinai, New York City, NY 10029, 10029USA.
  • Mendelev N; Icahn School of Medicine at Mount Sinai, New York City, NY 10029, 10029USA.
  • Fowler VG; Division of Infectious Diseases, Duke University, Durham, NC 27710, USA.
  • McClain MT; Division of Infectious Diseases, Duke University, Durham, NC 27710, USA.
  • Miller CM; Icahn School of Medicine at Mount Sinai, New York City, NY 10029, 10029USA.
  • Mofsowitz S; Icahn School of Medicine at Mount Sinai, New York City, NY 10029, 10029USA.
  • Nair VD; Icahn School of Medicine at Mount Sinai, New York City, NY 10029, 10029USA.
  • Nudelman G; Icahn School of Medicine at Mount Sinai, New York City, NY 10029, 10029USA.
  • Evans TG; Barinthus Biotherapeutics, Harwell, Oxfordshire, UK.
  • Castellino F; Biomedical Advanced Research & Development Authority-Administration for Strategic Preparedness & Response,Washington, DC 20201, USA.
  • Ramos I; Icahn School of Medicine at Mount Sinai, New York City, NY 10029, 10029USA.
  • Rirak S; Icahn School of Medicine at Mount Sinai, New York City, NY 10029, 10029USA.
  • Ruf-Zamojski F; Icahn School of Medicine at Mount Sinai, New York City, NY 10029, 10029USA.
  • Seenarine N; Icahn School of Medicine at Mount Sinai, New York City, NY 10029, 10029USA.
  • Soares-Shanoski A; Icahn School of Medicine at Mount Sinai, New York City, NY 10029, 10029USA.
  • Vangeti S; Icahn School of Medicine at Mount Sinai, New York City, NY 10029, 10029USA.
  • Vasoya M; Icahn School of Medicine at Mount Sinai, New York City, NY 10029, 10029USA.
  • Yu X; Icahn School of Medicine at Mount Sinai, New York City, NY 10029, 10029USA.
  • Zaslavsky E; Icahn School of Medicine at Mount Sinai, New York City, NY 10029, 10029USA.
  • Ndhlovu LC; Division of Infectious Diseases, Department of Medicine, Weill Cornell Medicine, New York, NY 10021, USA.
  • Corley MJ; Division of Infectious Diseases, Department of Medicine, Weill Cornell Medicine, New York, NY 10021, USA.
  • Bowler S; Division of Infectious Diseases, Department of Medicine, Weill Cornell Medicine, New York, NY 10021, USA.
  • Deeks SG; University of California San Francisco, San Francisco, CA 94143, 94143USA.
  • Letizia AG; Naval Medical Research Unit INDO PACIFIC, Singapore.
  • Sealfon SC; Icahn School of Medicine at Mount Sinai, New York City, NY 10029, 10029USA.
  • Woods CW; Division of Infectious Diseases, Duke University, Durham, NC 27710, USA.
  • Spurbeck RR; Health Business Unit, Battelle Memorial Institute, Columbus, OH 43201, USA.
Epigenomics ; 16(14): 1013-1029, 2024.
Article en En | MEDLINE | ID: mdl-39225561
ABSTRACT

Aim:

The epigenome influences gene regulation and phenotypes in response to exposures. Epigenome assessment can determine exposure history aiding in diagnosis.Materials &

methods:

Here we developed and implemented a machine learning algorithm, the exposure signature discovery algorithm (ESDA), to identify the most important features present in multiple epigenomic and transcriptomic datasets to produce an integrated exposure signature (ES).

Results:

Signatures were developed for seven exposures including Staphylococcus aureus, human immunodeficiency virus, SARS-CoV-2, influenza A (H3N2) virus and Bacillus anthracis vaccinations. ESs differed in the assays and features selected and predictive value.

Conclusion:

Integrated ESs can potentially be utilized for diagnosis or forensic attribution. The ESDA identifies the most distinguishing features enabling diagnostic panel development for future precision health deployment.
This article introduces ESDA, a new analytic tool for integrating multiple data types to identify the most distinguishing features following an exposure. Using the ESDA, we were able to identify signatures of infectious diseases. The results of the study indicate that integration of multiple types of large datasets can be used to identify distinguishing features for infectious diseases. Understanding the changes from different exposures will enable development of diagnostic tests for infectious diseases that target responses from the patient. Using the ESDA, we will be able to build a database of human response signatures to different infections and simplify diagnostic testing in the future.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Staphylococcus aureus / Epigenómica / Aprendizaje Automático / COVID-19 Límite: Humans Idioma: En Revista: Epigenomics Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Staphylococcus aureus / Epigenómica / Aprendizaje Automático / COVID-19 Límite: Humans Idioma: En Revista: Epigenomics Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos
...